Monopar Therapeutics Inc.
MNPRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Valued at $474.2M, MNPR is a small-cap name in its sector. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Market Cap
$474.2M
Beta
1.51
P/E (TTM)
—
P/E (Fwd)
-36.88
EPS (TTM)
$-2.20
EPS (Fwd)
$-1.92
ROE
-19.5%
ROA
-14.6%
Cash
$134.3M
Total Debt
$205,663
Free CF
-$6.1M
52W Change
-13.4%
Annual Financials
Cash vs Debt
Where MNPR stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, MNPR finished 15.56% below its 150-day moving average ($82.03) and 9.90% below its 200-day moving average ($76.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MNPR overbought or oversold?
At the October 19, 2026 close, MNPR's RSI(14) was 24.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Monopar Therapeutics Inc. holds $134.3M in cash against $206K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$6.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -19.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Monopar Therapeutics Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, MNPR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing MNPR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.